deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT06870058

A Study of NH280105 in Healthy Adult Participants

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose of Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NH280105 in Healthy Adult Participants

Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd.

Conditions Alzheimer Disease
Interventions NH280105- MAD NH280105- SAD Placebo
Updated 4 times since 2025 Last updated: Jan 13, 2026 Started: Mar 12, 2025 Primary completion: Nov 13, 2025 Completion: Nov 13, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Jiangsu Nhwa Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshotNot Yet Recruiting~Jul 2025 – ~Jan 2026 · 6 months · monthly snapshotRecruiting~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1

  2. Jan 2026 — Feb 2026 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  3. Jul 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Apr 2025 — Jul 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
Data source: Jiangsu Nhwa Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations